- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00381173
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This is an open-label study of ZYC300 in the treatment of advanced stage malignancy of the kidney in patients who have not had previous immune-based therapies or treatment of advanced stage malignancies (cancerous growths) of the ovary, breast, colon, or hormone-refractory prostate in patients who have failed at least one but no more than two prior regimens of chemotherapy. Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
ZYC300 is a plasmid DNA formulated within biodegradable microencapsulated particles. This is the first time that ZYC300 and Cyclophosphamide will be given together. Cyclophosphamide is a chemotherapy drug approved by the FDA that has been used for many years in many different kinds of cancer. In this trial the study drug will be used to boost the immune system. Sometimes the immune system cannot fight infected or abnormal cells because of other cells called T reg cells. The T reg cells limit the immune systems attack on infected or abnormal cells. In this study, the hope is that Cyclophosphamide will inhibit the T regs cells so that the ZYC300 can work better to attack the cancer cells.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Dana-Farber Cancer Institute
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- M. D. Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
To be included in the study, patients must meet the following criteria:
Patients with:
Advanced stage malignancies who have failed treatment, including at least one, but no more than two, prior regimens of chemotherapy: Ovary, Breast, Colon, Hormone Refractory Prostate Cancer (HRPC), and renal.
- Evidence of measurable disease by clinical or radiographic assessment or by tumor biomarker (ovarian and prostate cancer).
- Age ≥ 18 years old.
- A baseline Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- A life expectancy > 6 months.
Adequate hematological function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as:
- Absolute lymphocyte count ≥ 1,000/mm^2
- WBC ≥ 3,000/mm^2
- Platelet count ≥ 75,000/mm^2
- Hemoglobin ≥ 9 g/dL
- Adequate renal function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as serum creatinine ≤ 1.5 X upper limit of normal.
Adequate hepatic function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as:
- Total bilirubin ≤ 1.5 X upper limit of normal, and
- SGOT and SGPT ≤ 2.5X upper limit of normal.
- An MRI of the brain, if clinically indicated, which is negative for parenchymal central nervous system metastases within 28 days prior to receipt of the first dose of cyclophosphamide. If a patient cannot undergo an MRI because of a medical contraindication, a contrast CT of the brain will be acceptable.
- A negative pregnancy test (blood or urine) within 14 days prior to first dose of cyclophosphamide (where applicable).
- Agree to use appropriate contraception from study entry until the end-of-observation visit.
- A signed informed consent form approved by the Institutional Review Board.
Exclusion Criteria:
Patients cannot participate in the study if any of the following apply:
- Have a history of parenchymal brain metastases.
Have received any of the following within 28 days prior to receiving the first dose of cyclophosphamide:
- Chemotherapy
- Radiation therapy
- Immunotherapy
- Systemic immunosuppressive drugs
- Glucocorticoids (inhalers for asthma are permitted)
- Investigational agent or experimental therapy
- Have received three or more biologic/targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors.
- Have initiated or reinitiated the use of hormonal agents within 28 days prior to receiving the first dose of cyclophosphamide. These drugs are allowed if treatment was initiated greater than 28 days prior to receipt of the first dose of cyclophosphamide.
- Have a history of bone marrow or stem cell transplantation.
- Have a history of treatment with fludarabine, 2-chlorodeoxyadenosine, 2-deoxycoformycin or similar compounds.
- Have a history of treatment with chronic systemic immunosuppressive drugs.
- Have an immunologic disorder such as immunodeficiency or other chronic auto-immune disease if deemed to be clinically significant.
- Have an active systemic infection requiring treatment.
- Are known to be positive for HIV antibody.
- Pregnant or lactating.
- Have a history of alcohol abuse, illicit drug use, or psychiatric disorder that would in the Investigator's opinion jeopardize protocol compliance or compromise the patient's ability to give informed consent.
- Have had prior ex vivo or in vivo DNA therapy (administration of viral vectors or plasmid DNA formulations) or cancer vaccines.
- Previous exposure to ZYC300 or amolimogene (HPV E6E7 plasmid; formerly known as ZYC101a).
Please note: There may be additional inclusion/exclusion criteria. The study center will determine if patients meet all of the criteria. If patients do not qualify for the trial, study personnel will explain the reasons. If patients do qualify, study personnel will explain the trial in detail using an IRB-approved informed consent, and answer any questions. Patients can then decide if they wish to participate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
|
Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300.
ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.
Periodo de tiempo: Within 14 days and 12 weeks post last dose of study drug (and 16 weeks post last dose for response confirmation, if applicable).
|
Within 14 days and 12 weeks post last dose of study drug (and 16 weeks post last dose for response confirmation, if applicable).
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.
Periodo de tiempo: Within the first 14 days and at each subsequent visit.
|
Within the first 14 days and at each subsequent visit.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Michael Silverman, MD, Eisai Inc.
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- vacuna
- cáncer de próstata refractario a hormonas
- terapia de genes
- ciclofosfamida
- vacuna contra el cancer
- cáncer de mama avanzado
- Citoxano
- cáncer de ovario avanzado
- terapia inmune
- terapia biológica
- Células T reguladoras
- ADN plásmido
- tumores malignos en etapa avanzada
- cáncer renal avanzado
- cáncer de colon avanzado
- MGI PHARMA
- ZYC3-002
- ZYC300
- Advanced stage malignancies-ovary, breast, colon, prostate
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades Renales
- Enfermedades urológicas
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Neoplasias Genitales Femeninas
- Enfermedades del sistema endocrino
- Enfermedades Ováricas
- Enfermedades anexiales
- Trastornos gonadales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de glándulas endocrinas
- Neoplasias Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Neoplasias colorrectales
- Neoplasias Renales
- Carcinoma De Célula Renal
- Neoplasias prostáticas
- Neoplasias Ováricas
- Neoplasias colónicas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Ciclofosfamida
Otros números de identificación del estudio
- ZYC3-002
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos